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Abstract
Malnutrition is common among HIV-infected individuals and is often accompanied by low serum levels of micronutrients.
Vitamin B-12 deficiency has been associated with various factors including faster HIV disease progression and CD4 depletion
in resource-rich settings. To describe prevalence and factors associated with sub-optimal vitamin B-12 levels among HIV-
infected antiretroviral therapy (ART) naı ¨ve adults in a resource-poor setting, we performed a cross-sectional study with a
retrospective chart review among individuals attending either the Mulago-Mbarara teaching hospitals’ Joint AIDS Program
(MJAP) or the Infectious Diseases Institute (IDI) clinics, in Kampala, Uganda. Logistic regression was used to determine
factors associated with sub-optimal vitamin B-12. The mean vitamin B-12 level was 384 pg/ml, normal range (200–900). Sub-
optimal vitamin B-12 levels (,300 pg/ml) were found in 75/204 (36.8%). Twenty-one of 204 (10.3%) had vitamin B-12
deficiency (,200 pg/ml) while 54/204 (26.5%) had marginal depletion (200–300 pg/ml). Irritable mood was observed more
among individuals with sub-optimal vitamin B-12 levels (OR 2.5, 95% CI; 1.1–5.6, P=0.03). Increasing MCV was associated
with decreasing serum B-12 category; 86.9 fl (65.1) vs. 83 fl (68.4) vs. 82 fl (68.4) for B-12 deficiency, marginal and normal B-
12 categories respectively (test for trend, P=0.017). Compared to normal B-12, individuals with vitamin B-12 deficiency had
a longer known duration of HIV infection: 42.2 months (627.1) vs. 29.4 months (623.8; P=0.02). Participants eligible for ART
(CD4,350 cells/ml) with sub-optimal B-12 had a higher mean rate of CD4 decline compared to counterparts with normal B-
12; 118 (6145) vs. 22 (6115) cells/ml/year, P=0.01 respectively. The prevalence of a sub-optimal vitamin B-12 was high in
this HIV-infected, ART-naı ¨ve adult clinic population in urban Uganda. We recommend prospective studies to further clarify
the causal relationships of sub-optimal vitamin B-12, and explore the role of vitamin B-12 supplementation in immune
recovery.
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Introduction
Reduced serum micronutrient levels are common among HIV-
infected individuals prior to antiretroviral therapy (ART) [1,2,3].
Sub-optimal vitamin B-12 has been reported in 10–35% of
individuals with HIV infection [3,4,5]. A number of factors have
also been associated with sub-optimal serum vitamin B-12. Among
them are faster HIV disease progression [3], CD4+ T-cell decline
[3,4,6] anemia [1], weight loss [1,7], diarrhea [1] neuro-cognitive
changes [8,9] and neuropathy/myelopathy [10].
In order to ascertain the need for micronutrient replacement,
World Health Organization (WHO) recommends that the extent
and nature of micronutrient depletion among populations of
interest be determined [11] since geographical, racial, dietary and
cultural differences may influence micronutrient levels especially in
low-income countries [12]. Supplemantion with vitamins could be
beneficial as noted among HIV-infected pregnant women who
received multivitamin supplements which resulted in higher CD4
and CD8 counts, lower viral loads, and a delayed progression to
WHO stage III and IV disease [13]. Vitamin B-12 may modulate
cellular immunity and has been shown to facilitate production of T
lymphocytes, as well as maintain lymphocyte counts within normal
range when administered to individuals with pernicious anemia
[14].
Although empirical multivitamin supplementation has been
shown to improve immune recovery, there is barely any data
regarding the burden as well as the clinical and laboratory
manifestations associated with vitamin B-12 depletion among
individuals receiving HIV/AIDS care in Africa. Currently,
vitamin B-12 assay is not a routine pre-ART test in resource-
limited settings and there is a paucity of data concerning vitamin
B-12 depletion and its role in immune recovery among HIV-
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prevalence of sub-optimal serum vitamin B-12 and its associated
factors among ambulatory, ART-naı ¨ve, HIV-infected adults at
two urban clinics in Kampala, Uganda.
Methods
Study Design and Selection Criteria
Between March and April 2010 we performed a cross-sectional
study with a retrospective chart review among HIV-positive,
ART-naı ¨ve adults ($18 years) attending either the Mulago-
Mbarara Teaching Hospitals’ Joint AIDS Program (MJAP) or the
Infectious Diseases Institute (IDI) clinic. Due to the increased
physiological demand for vitamin B-12 in pregnancy, we excluded
pregnant women.
Study Setting
Both the MJAP and IDI clinics are located within the Mulago
Hospital Complex and offer comprehensive care to HIV-infected
adults within the hospital’s catchment area. IDI offers free
outpatient HIV/AIDS care and has registered over 25,000 patients
since its inception in 2002, with about 10,000 actively in care, 7,000
of whom have been initiated on ART. The MJAP clinic is part of a
collaborative partnership between Makerere University College of
Health Sciences, Mbarara University Faculty of Medicine with
Mulago and Mbarara teaching hospitals, respectively. Currently
over 8000 patients are registered and in care at the MJAP clinic.
Both MJAP and IDI clinics offer ART-naı ¨ve individuals monthly
cotrimoxazole prophylaxis and biannual CD4 tests. Serum vitamin
B-12 assessment is not part of routine care and multivitamins are
only prescribed at the clinicians’ discretion.
Data Collection
From a list of registered ART-naı ¨ve participants attending the
clinic, we selected every 10
th participant until the sample size was
attained. For every participant that did not fulfill the inclusion
criteria, the next participant was approached to join in the study.
Selected participants were then reviewed by the investigator and
requested to provide written informed consent in either Luganda
or English (depending on language of preference). The study
questionnaire was then administered together with a clinical
examination to obtain clinical parameters. The participants’ chart
were also reviewed for the date of HIV diagnosis, CD4 count at
diagnosis, history of opportunistic infections, WHO disease stage
and prescription records for vitamin B-12 containing supplements.
Participants’ weight and height were measured using a calibrated
weight scale and height board respectively. Six milliliters (mls) of
blood were drawn by a laboratory technician of which 3 mls was
used for complete blood cell count (CBC) and peripheral film, and
the other 3 mls for serum vitamin B-12 assay. For participants that
did not have a CD4 count within 3 months prior to study visit, an
extra 3 ml of blood was drawn for CD4 count estimation. Samples
were delivered to a laboratory daily within six hours of collection.
Subjects found with vitamin B-12 deficiency (,200 pg/ml)
received 3 doses of 1 mg parenteral vitamin B-12 in addition to
the nutritional counseling while those marginal B-12 (200–
300 pg/ml) only got nutritional counseling.
Laboratory Assays
CBC was measured at the Makerere University-John’s Hopkins
University (MUJHU) core laboratory at the IDI, which maintains
accreditation by the College of American Pathologists. A thin film,
stained with Giemsa, was used to study the blood cell morphology.
CD4 counts were estimated by flow cytometry from either the IDI
or MJAP laboratories. Vitamin B-12 levels were measured using
the Roche diagnostics Elecsys 2010 immunoassay at Ebenezer
clinical laboratories, a Kampala laboratory accredited by the
South African National Accreditation System (SANAS) and the
International Organization for Standardization (ISO).
Ethics Statement
Ethical approval for this study was obtained from the
Institutional Review Board (IRB) of the College of Health
Sciences, Makerere University and the Scientific Review Com-
mittee of the Infectious Diseases Institute. All participants
provided written informed consent.
Statistical Analysis
Data were entered into an Epidata database before being
exported and analyzed in STATA version 12 (STATA Corp,
College Station, TX) software. Continuous variables were
presented as either medians or means depending on the
distribution of the data. We used the Student t-test to compare
means and the Mann-Whitney U test to compare medians.
Categorical variables were analyzed and presented as frequencies
and percentages; they were compared using the chi-square and
Fisher’s exact tests as appropriate. The prevalence of sub-optimal
serum vitamin B-12 was expressed as the proportion of
participants with sub-optimal serum vitamin B-12 over the total
number of participants with a vitamin B-12 result. The main
outcome of this study was sub-optimal vitamin B-12 serum level
defined as a value below 300 pg/ml (221 pmol/L) [5,11]. Other
outcomes evaluated included vitamin B-12 deficiency defined as a
level less than 200 pg/ml (148 pmol/L) and marginal B-12
depletion defined as a level between 200–300 pg/ml (148–
221 pmol/L) [5,11]. Change in CD4 count was the difference
between CD4 count at the time of B-12 assessment (current CD4
count) and the CD4 count at HIV diagnosis. The rate of change in
CD4 count was derived from the change in CD4 count and the
time between HIV diagnosis date and study date (B-12 assessment
date). We defined anemia as hemoglobin level ,10 g/dl. Bivariate
analysis was done to determine association between sub-optimal
vitamin B-12 and other factors.
We used multivariate logistic regression to determine the
independent association between predictors and sub-optimal B-
12 deemed appropriate based on prior published work and
biologic plausibility. From our substantive knowledge of the
possible causal relationships, we generated Directed Acyclic
Graphs (DAGs) to best define the relationships first. We then
used multivariate logistic models based on these DAGs and we
present both adjusted and unadjusted estimated odds ratios for
relationships between the predictors we studied and sub-optimal
vitamin B-12. Among the predictors, age, gender, occupation,
WHO disease stage, body mass Index (BMI),CD4 count at HIV
diagnosis and current CD4 count, CD4 count change, rate of
change in CD4, known duration of HIV infection, anemia, MCV,
dietary intake and clinical factors including ‘‘irritable mood’’ were
studied. We used the Hosmer-Lemeshow test to rule out gross lack
of fit in the final models we present. We repeated multivariate
models in two sensitivity analyses; the first for participants who
had not taken vitamin B-12 containing supplements, and a second
for participants eligible for ART-based on a CD4 cut-off of ,350
cells/mL.
Results
Of the 210 participants screened, 152 were from IDI and 58
from MJAP. Out these, five were excluded (three were pregnant,
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have blood drawn. We present data for 204 enrolled participants.
The mean age of the study participants was 34.4 (69.4) years with
72% of them females2consistent with the demographic distribu-
tion of patients at both clinics. The mean serum vitamin B-12 level
for all study participants was 384.6 pg/ml (6197.7) while the
median B-12 level was 349 pg/ml [Inter Quartile Range (IQR)
254.2–450.5 pg/ml].
Seventy-five (36.8%) participants had sub-optimal serum
vitamin B-12 (,300 pg/ml) with 21 (10.3%) being vitamin B-
12 deficient (,200 pg/ml) and 54 (26.5%) with marginal vitamin
B-12 depletion (200 to 300 pg/ml). Prevalence of sub-optimal B-
12 did not vary by study site (Table 1). The distribution of
characteristics such as age, gender, level of education, WHO
stage and opportunistic infections and/or HIV-associated disease
conditions were largely similar for both normal and sub-optimal
B-12 categories (Table 1). The proportion of participants with
irritable mood however, was higher among participants with sub-
optimal vitamin B-12 compared to those with normal vitamin B-
12 levels (25.3% vs. 13.3%; P=0.03) (Table 1). Anemia,
leucopenia and thrombocytopenia were not associated with
sub-optimal vitamin B-12 level but mean MCV for participants
with B-12 deficiency was higher for sub-optimal B-12 compared
to normal B-12 though this was not statistically significant
(Table 1). Compared to marginal and normal B-12 levels
however, individuals with B-12 deficiency had higher mean
MCV: 83 fl (68.4) vs. 82 fl (68.4) 86.9 fl (65.1) respectively.
This trend of increasing MCV across decreasing serum B-12
category was statistically significant (test for trend, P=0.017).
Five participants had anemia (hemoglobin ,10 g/dl) and sub-
optimal vitamin B-12. One of these had B-12 deficiency while
the other two had marginal depletion. Two of the five
participants with anemia also had a mean corpuscular volume
(MCV) .100fl.
Known duration of HIV infection was slightly longer for
individuals with sub-optimal vitamin B-12 though this difference
was not statistically significant (Table 1). Considering B-12
deficiency, marginal depletion and normal B-12 categories, we
found a statistically significant association in the trend of
increasing mean duration of known HIV infection with decreasing
B-12 category: with normal B-12 at 29.4 months (623.8),
marginal B-12 at 33.6 (630.0) and B-12 deficiency 42.2 months
(627.1) (test for trend, P=0.03).
Use of vitamin B-12 containing supplements did not vary
between the B-12 categories. Further, all participants surveyed
reported taking animal source foods as part of their diet. No
participant reported being a strict vegetarian. Only 5.8% of
participants reported having taken animal source foods less than
once in the previous year and this did not vary with serum vitamin
B-12 category. Reported use of alcohol was not different between
the groups. Use of proton pump inhibitors and H2 receptor
antagonists was 2.5% and 3.5% respectively and none of the
participants surveyed reported use of metformin.
Adjusted for age, gender, BMI, supplement use, occupation,
known duration with HIV and current CD4 with multivariate
logistic regression, sub-optimal B-12 was associated with irritable
mood, OR 2.5 (95% CI; 1.1–5.6, P=0.03) (Table 2). Female sex,
anemia, WHO stage, being employed and supplement use were
associated with sub-optimal B-12 but these findings were
inconclusive based on the corresponding p-value and 95% CI
for the odds ratios (Table 2).
In the sensitivity analysis for participants without history of B-12
supplementation we found statistically significant adjusted odds
ratios for the association between irritable mood and sub-optimal
B-12 at 3.2 (95% CI: 1.1–9.3, P=0.04) (Table 3). Average MCV
was also significantly higher among the participants with a sub-
optimal B-12 level at 85.0 fl (67.5), compared to those with
normal B-12 at 81.0 fl (68.4), P=0.02. The adjusted odds ratios
for this association were marginally statistically significant; 1.1
(95%CI; 1.0–1.1, P=0.03) (Table 3). The mean duration of
known HIV infection, was also statistically significantly higher
among participants with sub-optimal B-12 compared to those with
normal B-12 at 37 (628.0) vs. 26 (622.4) months (P=0.017),
respectively. This association remained marginally significant with
multivariate logistic regression; OR 1.0 (95%CI; 1.0–1.1, P=0.02)
(Table 3). Participants with sub-optimal B-12 had significantly
higher mean BMI, 25.4 Kg/m
2 (65.2) compared to those with
normal B-12, 23.0 Kg/m
2 (64.2) P=0.006. Adjusted for age, sex,
occupation, current CD4, and known duration with HIV, BMI
had just marginal statistical association with sub-optimal B-12, OR
1.1 (95%CI; 1.0–1.3, P=0.02) (Table 3). For individuals who
reported use of supplements, sub-optimal B-12 was associated with
female sex OR 5.2 (95%CI; 1.3–20.4, P=0.02).
Among participants eligible for ART (CD4#350 cells/ml) at
time of study, mean rate of CD4 decline was significantly higher
for patients with sub-optimal B-12 at 118 (6145) compared to 22
(6115) cells/ml/year, P=0.01, for patients with normal B-12
levels. This association was marginally significant with multivariate
analysis OR 1.0 (95%CI; 0.9–1.1, P=0.02) (Table 4). In this
group however, irritable mood was strongly associated with sub-
optimal B-12: OR 8.6 (95%CI; 2.0–37.0, P=0.004) (Table 4). We
found no associations with sub-optimal vitamin B-12 levels among
individuals with CD4.350 cells/ml.
Discussion
We found a high prevalence (36.8%) of sub-optimal serum
vitamin B-12 (,300 pg/ml) in this ambulatory, urban, HIV-
infected, ART-naı ¨ve population. Presently, we have limited
published data on serum vitamin B-12 levels among populations
in sub-Saharan Africa to make direct comparisions with.
Considering other work from the region, a study among school
children in rural Kenya found 30.5% of them B-12 deficient
(,200 pg/ml) while 37.7% had marginal B-12 levels (200–
300 pg/ml) [15]. Another study among pregnant Sidama women
in southern Ethiopia revealed that 23% had vitamin B-
12,150 pmol (,211 pg/ml) [16]. These two studies uniquely
highlight the high prevalence of sub-optimal vitamin B-12
depletion among rural populations in Africa. Importantly though,
the HIV status of participants in these two above studies was not
assessed. Putting our findings in perspective, the HIV-infected,
ART-naı ¨ve individuals in this study had a lower mean vitamin B-
12 level (384 pg/ml) than the mean B-12 level reported in a
population of healthy, young, Ugandan, university students
(469 pg/ml) [17]. Nontheless there is still a need to evaluate
vitamin B-12 levels among rural HIV-infected populations in
subsaharan Africa since these individuals are prone to higher levels
of poverty that which threatens food security by significantly
reducing availability and quality of their nutrition.
Studies from resource-rich settings also corroborate the sub-
opitmal B-12 levels among HIV-infected individuals comapred to
their HIV-uninfected counter parts [3,4,6,9]. Addtionally, there is
also a wide variation in the prevalence estimates of B-12 depletion
among HIV-infected individuals in these studies
[3,4,6,9,10,18,19]. This is possibily due to the corresponding wide
variability in B-12 cut-off values and patient populations used. At a
cut-off value of ,200 pg/ml, 10.3% of the ART naı ¨ve partic-
ipants in the present study were vitamin B-12 deficient. Similarly,
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deficiency ranged between 12 and 13% at comparable cut-off
values. In a retrospective study among homosexual and hetero-
sexual men in the Baltimore-Washington DC area, the prevalence
of vitamin B-12 deficiency (,120 pmol/l, equivalent to 163 pg/
ml) was 12% [19] while Hepburn et al. in Houston Texas,
reported a prevalence of 13.1% using a cut-off value of 211 pg/ml
[4]. Among 200 HIV-positive individuals in Montreal, Canada, a
higher prevalence of 30.5% at a higher cut-off of ,300 pmol/l
(equivalent to 406 pg/ml) was reported [6]. We note that in some
of the aforementioned studies, individuals had taken antiretroviral
therapy in varying degrees [4,5,8,9,16,20] making their findings
not directly comparable to ours. Even so, the 36.8% prevalence of
sub-optimal B-12 we find in our study is still high given the 37.5%
reported use of vitamin B-12 containing supplements overall.
We found that sub-optimal vitamin B-12 was associated with an
‘‘irritable mood’’. This finding has not been reported before
although other neuro-cognitive disorders have been associated
with sub-optimal vitamin B-12 such as; myelopathy [10],
neuropathy [10], cognitive changes [8,9] among HIV-infected
adults [20]. In fact, mood disorders such as bipolar affective
disorders have been reported among HIV-infected individuals
even in Uganda [21,22]. On the other hand, multivitamin
supplementation (B-complex, C and E) has been shown to be
protective from depression with a 22% reduction in risk (P=0.005)
in a randomized control trial among HIV-positive pregnant
Table 1. A comparison of characteristics by serum vitamin B-12 group among adult HIV-infected ART naı ¨ve participants at two
urban HIV clinics in Uganda, in April 2010.
Characteristic Category
Sub-optimal Vitamin B-12
(,300 pg/ml) N=75
Normal Vitamin
B-12 (.300 pg/ml)
N=129 P-value
Age (years), N (%) ,29 24(32.0) 49(38.3) 0.66
30–49 46(61.3) 70(54.7)
.50 5 (6.7) 9(7.0)
Female, N (%) 57 (76.0) 90 (69.8) 0.34
Married, N (%) 41(54.7) 67(51.9) 0.71
Education, N (%) No Education 6 (8.0) 15 (11.6) 0.26
Basic Education 28 (37.3) 59 (45.7)
Secondary/Tertiary 41 (54.7) 55 (42.6)
Occupation Unemployed 13(17.3) 35(26.9) 0.12
Employed 62(82.7) 95(73.1)
Study Site, N (%) IDI 56 (37.8) 92 (62.2) 0.55
MJAP 19 (33.3) 38 (66.7)
Use of B-12 Supplement, N (%) 32(42.7) 45(34.9) 0.27
Alcohol intake, N (%) 26(34.7) 54(42.2) 0.29
WHO Staten (%) WHO Stage I & II 64 (85.3) 108 (83.7)
WHO Stage III & IV 11 (14.7) 21 (16.3) 0.76
Irritable mood, N (%) 19 (25.3) 17 (13.2) 0.03
Paraesthesia, N (%) 2 (2.7) 5 (3.9) 0.65
Opportunistic Infections, N (%) Tuberculosis 7(9.3) 12(9.4) 0.99
Oral candidiasis 20(26.7) 39(30.5) 0.56
Herpes zoster 15(20.0) 18(14.1) 0.27
Genital sores 14(18.7) 30(23.4) 0.43
Recurrent Pneumonia 2(2.7) 10(7.8) 0.14
Skin rashes(PPE) 30(40.0) 68(53.1) 0.07
Diarrhea 5(3.9) 5(3.9) 1.00
Anemia, N (%) 5 (6.7) 18 (13.9) 0.11
BMI, mean (SD)
a 24.7(4.7) 23.4(4.6) 0.07
MCV (fl), mean (SD) 84.0(7.8) 82.0(8.4) 0.08
CD4 at diagnosis (cells/ml)median (IQR)
a 542 (410–714) 501(370–662) 0.11
Current CD4 (cells/ml)median (IQR) 406 (326–607) 418 (314–547) 0.71
CD4,350 (cells/ml)N( % ) 25 (33.3) 40 (30.8) 0.70
Known duration with HIV (months), mean (SD)
a 36.1 (30.0) 29.3(23.8) 0.09
IQR- Inter Quartile Range, BMI- Body Mass Index, WHO-World health Organization, MCV-Mean Corpuscular Volume, Hb- Hemoglobin. IDI- Infectious Disease
Institute, MJAP- Mulago-Mbarara Teaching Hospitals’ Joint AIDS Program T-tests were used to compare means and the chi-square for proportions, except where
mentioned.
aSome missing data. N=113 for Normal B-12 & 70 for Sub-Optimal B-12.
doi:10.1371/journal.pone.0040072.t001
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was not possible in this study, therefore more in-depth neuropsy-
chiatric assessment and prospective studies are required to further
understand the association between sub-optimal vitamin B-12,
irritable mood and affective disorders among HIV-infected adults
with and without antiretroviral therapy.
We observed that the participants with sub-optimal vitamin B-
12 had higher MCVs compared to those with normal vitamin B-
12 levels. This association was still statistically significant with
multivariate analysis after eliminating individuals reported to have
taken B-12 containing supplementation. Macrocytosis has been
observed in previous studies among individuals with sub-optimal
vitamin B-12 [24]. Moreover, previous studies have reported that
participants with low vitamin B-12 were also more likely to have
clinically advanced HIV disease with weight loss, diarrhea and
anemia [1,4,6,7,19,25]. Individuals in the present study did not
have advanced HIV disease since we studied ART naı ¨ve patients
who were probably slow long-term non-progressors with relatively
high CD4 counts and hence less advanced disease.
In addition, low BMI had been associated with sub-optimal B-
12 usually among very ill individuals with clinically advanced
disease [6]. Surprisingly, we found that participants with sub-
optimal B-12 levels had on average a higher BMI. Nutritional
assessment in the present study, which not only included
measurement of the BMI but also a dietary history, did not reveal
any association between low nutritional status and sub-optimal B-
12 levels as reported prior. The number of participants with sub-
optimal vitamin B-12 and clinical malnutrition was also low. This
may in part have resulted from improved HIV patient care at both
urban study sites where nutritional counseling and sometimes free
Table 2. Risk factors for sub-optimal vitamin B-12 among adult HIV-infected ART naı ¨ve individuals at two urban HIV clinics in
Uganda, in April 2010.
Predictor variable Unadjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Age 1.0 0.9–1.04 0.42 1.0
a 0.9–1.0 0.75
Female 1.4 0.7–2.7 0.30 1.7
a 0.8–3.9 0.19
Irritable Mood 2.2 1.1–4.6 0.03 2.5
a 1.1–5.6 0.03
Supplement use 0.7 0.4–1.3 0.25 0.7
a 0.4–1.3 0.30
WHO Stage III & IV 0.8 0.4–1.9 0.7 1.0
a 0.4–2.4 0.93
Occupation (Employed) 1.7 0.8–3.6 0.13 1.7
a 0.7–4.0 0.21
Current CD4 1.0 0.9–1.0 0.90 1.0
a 0.9–1.0 0.50
BMI 1.1 0.9–1.2 0.07 1.0
a 0.9–1.1 0.30
Known duration with HIV 1.1 1.0–1.3 0.08 1.0
a 1.0–1.1 0.24
Anemia 0.4 0.1–1.6 0.21 0.4
a 0.2–1.5 0.20
MCV 1.0 0.9–1.1 0.08 1.0
a 0.9–1.1 0.50
Rate of CD4 decline 1.0 0.9–1.0 0.32 1.0
b 0.9–1.0 0.24
aAdjusted for age, sex, BMI, supplement use, MCV, occupation, irritable mood, known duration with HIV, WHO disease stage and current CD4.
bAdjusted for,age, sex, BMI, WHO stage, supplement use.
BMI- Body Mass Index, MCV-Mean Corpuscular Volume, OR Odds Ratio, WHO-World health Organization.
doi:10.1371/journal.pone.0040072.t002
Table 3. Risk factors for sub-optimal serum vitamin B-12 among adult HIV-infected ART naı ¨ve participants who did not report
using vitamin B-12 containing supplements at two urban HIV clinics in Uganda, in April 2010.
Predictor variable Unadjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Age 1.0 0.9–1.04 0.9 0.9
a 0.8–1.0 0.09
Female 1.1 0.5–2.5 0.70 0.6
a 0.2–2.1 0.47
Irritable Mood 2.6 1.1–6.4 0.03 3.2
a 1.1–9.3 0.04
WHO Stage III & IV 1.9 0.4–2.5 0.90 1.9
a 0.6–6.2 0.30
Occupation (Employed) 1.9 0.7–4.5 0.20 1.9
a 0.6–6.1 0.27
Current CD4 1.0 0.9–1.0 0.80 1.0
a 0.9–1.0 0.90
BMI 1.1 1.0–1.2 0.01 1.1
a 1.0–1.3 0.01
Known duration with HIV 1.2 1.0–1.5 0.02 1.0
a 1.0–1.1 0.02
Anemia 0.6 0.2–2.5 0.50 0.6
a 0.1–2.6 0.40
MCV 1.1 1.0–1.1 0.02 1.1
a 1.0–1.2 0.02
Rate of CD4 decline 1.0 0.9–1.0 0.82 1.0
b 0.9–1.0 0.46
aAdjusted for age, sex, BMI, supplement use, MCV, occupation, irritable mood, known duration with HIV, WHO disease stage and current CD4.
bAdjusted for,age, sex, BMI, WHO stage, supplement use.
BMI- Body Mass Index, MCV-Mean Corpuscular Volume, OR Odds Ratio, WHO-World health Organization.
doi:10.1371/journal.pone.0040072.t003
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fully explain the association between higher BMI and sub-optimal
B-12 that we find and further evaluation is warranted preferably
with a prospective study design.
Individuals with sub-optimal vitamin B-12 levels in this study
also had a longer known duration of HIV infection especially
when those who did not report intake of supplements were
considered. This finding may suggest that the depletion of vitamin
B-12 may result from progression of HIV disease as noted
elsewhere [4,6,19,25]. The higher rate of CD4 decline noted
among patients with sub-optimal vitamin B-12 levels with CD4
cells ,350, may also suggest that the depletion of vitamin B-12
may result from progression of HIV disease [4,6,19,25]. The
reduced vitamin B-12 stores in both cases possibly resulting from
increased demand to replace CD4 cells depleted by actively
replicating HIV virus. In the present study, we did not measure
baseline B-12 (at the time of HIV diagnosis) so this theory is
impossible to prove. Further evaluation of the effect of HIV
disease progression and recovery on sub-optimal vitamin B-12 and
vice versa are thus warranted. Understanding this relationship
would be valuable in ascertaining the short and long-term effects
of vitamin B-12 replacement as an adjuvant to ART.
There were some limitations in the present study that should be
considered while interpreting our findings. When adjusting for
measures of social economic status as a determinant of food
security in our models, we used a proxy measure (occupation) and
this may have been inadequate to fully account for the role social
economic status plays in vitamin B-12 depletion. In addition, our
results may not be easily generalized to HIV-infected rural
populations that have a relatively different risk profile for the
development of sub-optimal vitamin B-12. With the present study
design, reverse causality cannot also be ruled out for the factors we
found associated with sub-optimal vitamin B-12.
We found a high prevalence of vitamin B-12 depletion among
ambulatory HIV-infected, ART-naı ¨ve adults attending HIV/
AIDS care in an urban setting in Uganda. Sub-optimal B-12 was
associated with longer duration of HIV infection, higher MCV,
irritable mood and higher rate of CD4 decline among individuals
eligible for ART. We recommend prospective studies to further
clarify the role of vitamin B-12 in HIV disease progression and
immune recovery in both rural and urban populations. Individuals
with HIV and mood disorders may benefit from assessment of
serum vitamin B-12 level.
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